Your browser doesn't support javascript.
loading
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Sastre, J; García-Alfonso, P; Viéitez, J M; Cano, M T; Rivera, F; Reina-Zoilo, J J; Salud-Salvia, A; Quintero, G; Robles-Díaz, L; Safont, M J; La Casta, A; Gil, S; Polo, E; Asensio-Martínez, E; García-Paredes, B; López, R L; Guillot, M; Valladares-Ayerbes, M; Aranda, E; Díaz-Rubio, E.
Afiliação
  • Sastre J; Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain. Electronic address: jsastrev@salud.madrid.org.
  • García-Alfonso P; Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Viéitez JM; Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Cano MT; Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba, Spain.
  • Rivera F; Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  • Reina-Zoilo JJ; Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Seville, Spain.
  • Salud-Salvia A; Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain.
  • Quintero G; Medical Oncology, Hospital Lucus Augusti, Lugo, Spain.
  • Robles-Díaz L; Medical Oncology, Hospital 12 de Octubre, Madrid, Spain.
  • Safont MJ; Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain.
  • La Casta A; Medical Oncology, Hospital de Donostia, Guipúzcoa, Spain.
  • Gil S; Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, Malaga, Spain.
  • Polo E; Medical Oncology, Hospital Miguel Servet, Zaragoza, Spain.
  • Asensio-Martínez E; Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain.
  • García-Paredes B; Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
  • López RL; Medical Oncology, University Clinical Hospital and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela, Spain.
  • Guillot M; Medical Oncology, Hospital Son Espases, Palma de Mallorca, Spain.
  • Valladares-Ayerbes M; Medical Oncology, Complejo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica (INIBIC), A Coruña, Spain.
  • Aranda E; Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba, Spain.
  • Díaz-Rubio E; Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
ESMO Open ; 6(2): 100062, 2021 04.
Article em En | MEDLINE | ID: mdl-33711671
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Células Neoplásicas Circulantes Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Células Neoplásicas Circulantes Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article